MUSK and myasthenia gravis: Pathogenic IgG autoantibodies targeting the acetylcholine receptor (AChR) are detected in approximately 85% of individuals with myasthenia gravis (MG), whilst IgG antibodies directed against other components of the neuromuscular junction, such as muscle‐specific tyrosine kinase (MuSK) and low‐density lipoprotein receptor related protein 4, are identified in approximately 6% and 2% of patients with MG, respectively [4].